Shareholders Urged to Vote Their GREEN Proxy or
GREEN VIF to Strengthen Board with Three New, Highly Qualified
Independent Nominees
ILJIN SNT Co., Ltd. (“ILJIN”) today sent a letter to
shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP)
(“Aurinia” or the “Corporation”), highlighting the
governance failures and director conflicts under the current board
of directors, correcting misleading information disseminated to
shareholders by Aurinia on June 7, 2019 and urging shareholders to
vote their GREEN proxy or GREEN VIF to strengthen the board.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190610005681/en/
Aurinia Board of Directors Web of
Interconnected Relationships (Graphic: Business Wire)
ILJIN, a founding shareholder of Aurinia which together with
certain affiliates holds an approximately 14% ownership interest in
Aurinia, is seeking support for three exceptional nominees for
election as directors at the annual meeting: Dr. Robert Foster,
Mr. Soon-Yub (Samuel) Kwon and Dr. Myeong-Hee Yu. These
director nominees represent an independent and highly experienced
minority slate of directors who are committed to bringing both good
governance and their technical, business and scientific expertise
to the progression and ultimate commercialization of Aurinia’s
impressive pipeline of pharmaceutical solutions.
Young-Hwa Kim, Chief Executive Officer of ILJIN, said, “At this
pivotal moment for Aurinia, it desperately needs an independent,
experienced board of directors that is aligned with shareholders’
interests and can effectively support management with the execution
of a long-term strategy to realize voclosporin’s tremendous
potential. The status quo is unsustainable. Shareholders cannot
afford to continue with a revolving door of CEOs, bloated executive
compensation or a myopic, all-or-nothing strategy, all of which are
the legacy of the current board, handpicked by its former chairman,
Mr. Richard Glickman.”
Mr. Kim also noted, “We were disappointed to read Aurinia’s
recent press release which criticized ILJIN, its longest and most
committed shareholder, as an ‘activist,’ for having the audacity to
propose numerous standard-practice governance improvements that are
critically necessary to introduce independence to a conflicted and
myopic board. To also deliberately misrepresent that ILJIN is
seeking to control the board of directors demonstrates disregard
for the truth and disrespect for shareholders. As we have
communicated consistently and repeatedly, ILJIN is nominating a
total of only three directors and has specifically recommended
shareholders withhold their votes from Dr. Hyuek Joon Lee, ILJIN’s
current board representative.
“Aurinia is simply trying to scare shareholders into maintaining
the status quo for the benefit of the Glickman cadre of conflicted
directors. Aurinia’s future is in shareholders’ hands, and we ask
them to support our minority slate at the upcoming annual general
meeting, and not succumb to this misdirection and
fearmongering.”
Shareholders are urged to read the circular and vote ONLY the
GREEN proxy or GREEN VIF on or before 5:00 p.m. (Mountain time) on
June 21, 2019, so that it can be deposited in advance of the proxy
cut-off. Shareholders who have already voted and wish to change
their vote in support of the three independent nominees can do so
by simply executing the Green proxy, as a later dated Green proxy
will cancel an earlier vote. Shareholders requiring any assistance
in executing their GREEN proxy or voting instruction form, can call
Gryphon Advisors Inc. at: 1-833-266-0365 or 1-416-661-6592 or email
inquiries@gryphonadvisors.ca.
For ease of voting, shareholders are encouraged to visit
www.AHealthierAurinia.com and click on the “Vote Now” button. A
copy of the information circular is available on Aurinia’s SEDAR
profile at www.sedar.com.
The full text of ILJIN’s letter to fellow Aurinia shareholders
follows:
June 10, 2019
Dear Fellow Shareholders,
As you know, ILJIN SNT Co., Ltd. (“ILJIN”, the
“Concerned Shareholder” or “we”) and its affiliated
companies (collectively, the “ILJIN Group”) are significant
shareholders of Aurinia Pharmaceuticals Inc. (“Aurinia” or
the “Corporation”) and long-time, enthusiastic believers in
the commercial potential of voclosporin.
We have for nearly six years remained behind the scenes,
attempting to quietly and constructively improve Aurinia’s
corporate governance and related executive compensation matters,
board composition, operational acumen and financial management
through active engagement with Aurinia’s board and management. For
the past two and a half years in particular we have made repeated,
good-faith efforts to engage Aurinia on these issues, including
identifying no fewer than 27 distinct deficiencies and potential
improvements on the basis of prevalent corporate governance
practices among Aurinia’s peers, including the adoption of
executive share ownership guidelines, director share ownership
guidelines and clawback policies.
To date, the current board has enacted NONE.
Against this backdrop of protracted attempts to facilitate
positive organizational change, all with nothing to show for it but
a string of broken promises, ILJIN finally determined to enlist the
assistance of other shareholders to reconstitute a minority of the
board to drive the changes that are so badly needed.
To support ILJIN’s call to action, we mailed you an information
circular dated June 2, 2019 (the “ILJIN Circular”)
containing a comprehensive analysis of Aurinia’s current
governance, independence, compensation and other problematic
practices that we believe conclusively demonstrates the depth of
the organizational dysfunction that must be uprooted for Aurinia to
thrive. To the extent you have not yet reviewed the ILJIN Circular
we would invite you to visit www.aHealthierAurinia.com or
www.sedar.com under Aurinia’s SEDAR profile or reach out to our
strategic shareholder advisor and proxy solicitor Gryphon Advisors
Inc. at: 1-833-266-0365 or 1-416-661-6592 or email
inquiries@gryphonadvisors.ca.
On June 7, 2019, Aurinia finally responded to the ILJIN
Circular. Regrettably, though not unexpectedly given our
experiences over the past several years of attempted engagement,
Aurinia elected to:
- both deny there is anything wrong with their
corporate governance practices while simultaneously committing to
hollow promises of improvement;
- denigrate their largest shareholder, ILJIN,
as an “activist” notwithstanding the litany of obvious deficiencies
that ILJIN has identified in good faith over many years of patient
ownership and the investment of over $60 million;
- blame ILJIN for this costly and unnecessary
proxy contest;
- knowingly
mischaracterize our nomination of three independent
nominees with no prior relationship to ILJIN or each other as an
attempt to gain control of the board;
- attack our minority slate as lacking
commercialization expertise when it has as much or
more commercialization expertise than the directors ILJIN
would propose to replace; and
- attack ILJIN’s flexibility and attempts to
find a complement of directors that would be agreeable to Aurinia
in a negotiated compromise board, while foisting upon shareholders
an 11th hour nominee pulled from Mr. Glickman’s rolodex and
professing to have run a comprehensive board refreshment
process.
Aurinia’s response to the ILJIN Circular can leave absolutely
no doubt:
YOUR BOARD IS CONFLICTED AND REQUIRES
IMMEDIATE CHANGE
Management’s claims of a “board renewal” are spin.
While the company has presented shareholders with a narrative of
change borne out of an ongoing evaluation of board composition,
nothing could be further from the truth.
It is clear that Aurinia only undertook a limited board
refreshment in the immediate run-up to the annual general meeting
this year because the board realized that its repeated stonewalling
of ILJIN’s requests for change were coming to a head and it was
hopeful that it could present shareholders with a believable story
of self-improvement.
Second, it is just as clear that this board refreshment process
was half-hearted, having begun by identifying its own current
corporate solicitor, Mr. Stephen Robertson, as a suitable
independent nominee, only to then trump the insanity by now
offering shareholders Aurinia’s former solicitor and long-time
colleague of Mr. Glickman, Mr. R. Hector MacKay-Dunn.
Are shareholders to believe that countless worthy candidates
were considered and ultimately rejected by this board because they
failed to meet the unimpeachable degree of expertise,
accomplishment and independence resident in Aurinia’s two corporate
solicitors?
To present Mr. MacKay-Dunn as the face of a new, independent
board only affirms the issues of the current board. Even a cursory
review of his professional history reveals that Mr. MacKay-Dunn is
a long-time trusted lieutenant of Mr. Richard Glickman. His
addition to the board would serve as just one more brick in the
wall of hand-picked Glickman affiliates that stands in the way of
the adoption of any meaningful reforms and makes a mockery of any
professed concern for independence.
Plain and simple, this is not an independent board – it is a
legacy of relationships
The chart below illustrates the web of interconnected
relationships between each of the current board members (excluding
ILJIN’s representative, Dr. Joon Lee) and former Chairman and Chief
Executive Officer Mr. Richard Glickman.
Aurinia Board of Directors Web of Interconnected
Relationships (See Graphic Above)
What is the net effect of these interlocking relationships? Let
us give you one example.
On Friday, May 24, 2019, we provided our advance notice to
Aurinia in respect of our intention to nominate independent
directors for consideration by shareholders at the upcoming annual
general meeting. Rather than engage in constructive discussions
with us, the Aurinia Board felt it imperative to inform Mr.
Glickman (no longer a director or officer of the company) of this
material, non-public information to which he very quickly called
one of our highly qualified and independent nominees to berate him
for standing for election.
If you needed confirmation as to lack of independence of this
board from the self-interested influences of Mr. Glickman, this
example shines bright as a warning to all shareholders.
Aurinia’s Reluctant Governance Improvements
– Baby Steps where Strides are Needed
Given how complacent Aurinia has been in relation to its
deficient governance practices over the past several years, it is
somewhat surprising how quickly it has trumpeted its very recent
governance improvements. What Aurinia has conveniently neglected to
mention, however, but which should be obvious to shareholders now,
is that all of such changes are the result of ILJIN’s pressure.
Without constant pressure and the potential for public
embarrassment, Aurinia’s board of directors would undertake no
meaningful improvement.
Each of the following, for instance, was undertaken only after
sustained pressure from ILJIN over a period of months:
1.
Separation of Roles of Chairman and
Chief Executive Officer – ILJIN had long expressed governance
concerns with Mr. Glickman being both the Chairman and CEO, even
with the ostensible independent management of the board residing in
the lead director, Mr. Lorin J. Randall. With the appointment of
Peter Greenleaf as Chief Executive Officer the roles were split to
reflect good corporate governance practice.
2.
Advisory Vote on Executive Compensation
– ILJIN had also long articulated concerns with Aurinia’s
compensation practices and ultimately suggested that in the
interests of increasing the ability of shareholders to exercise
some oversight on those practices Aurinia adopt a “say on pay”
advisory vote at the annual shareholders meeting. Aurinia has for
the first time proposed such a resolution at the pending
meeting.
3.
Change Board Composition to Improve
Independence – Although the process by which Aurinia identified
and nominated Mr. MacKay-Dunn was flawed and resulted in an
entirely non-independent candidate being proposed for election at
the annual general meeting, recognition of the need to change at
all only arose as a result of ILJIN’s continued pressure for
improved governance practices. Mr. MacKay-Dunn was only nominated
by Aurinia at the eleventh hour and under heavy pressure from ILJIN
regarding Aurinia’s previous candidate, Mr. Stephen Robertson, the
corporate solicitor for Aurinia.
Each of those changes had to be forced upon an unwilling board
of directors. Unlike Aurinia’s current directors, ILJIN’s three
nominees can be expected to proactively implement best practices
for corporate governance and executive compensation rather than
begrudgingly adopt face-saving cosmetic changes. Aurinia
deserves directors that are more interested in your best interests
than defending their legacy and relationships.
The Hallmark of the Company Has Been a
Revolving Door of CEO’s and Bloated Compensation
In its six years of existence post-Isotechnika, Aurinia has had
six CEOs. On the other hand – and at the core of many of the
concerns ILJIN has about Aurinia’s governance – the Corporation had
only one Chairman during every one of these CEO appointments, Mr.
Richard Glickman.
It is clear that the CEO position has been nothing but a
revolving door for Aurinia during Mr. Glickman’s reign as
Chairman. Regardless of the stage of Aurinia’s growth, its
success in achieving objectives or its massive potential, CEOs
under Mr. Glickman and his board haven’t stuck around.
This revolving door has to stop moving. Mr. Glickman is
now retired and should no longer be influencing strategic direction
and the success of its current CEO, but this is clearly not the
case. Under the current web of Mr. Glickman’s hand-picked
directors, including his anointed successor Mr. George Milne as
Chairman, the same dynamics that have led to the constant departure
of prior CEOs and Aurinia’s current sky-high executive compensation
and muddled operational strategy will continue to play out in the
boardroom.
We shareholders cannot allow this to continue. The
Corporation, which should be governed and operated with a focus on
shareholder wealth creation, is instead operated as if it were Mr.
Glickman’s private company. It is incumbent on shareholders
to add independence and experience to our board to ensure that
Aurinia can benefit from the stability and consistency of a single,
unifying CEO during this critical period of transition.
Not only is the revolving door of CEOs bad for continuity, the
efficient discharge of strategic priorities and market perception,
it has been unbelievably costly for Aurinia and its shareholders.
After serving for a short period, these individuals keep their
large stock options or make arrangements to extend the exercise of
their stock options. Each time, shareholders have been left with
nothing but poor performance and severance costs. There can be no
doubt that Aurinia’s board has failed to provide the appropriate
strategic oversight and support necessary to retain its CEO and
enable them to succeed, and has repeatedly paid for its failures
through annual golden hellos and goodbyes to the benefit of insider
CEOs.
From its first full year following the merger with Isotechnika
through to and including 2018, total
compensation paid to the five highest paid executive officers grew
a total of approximately 23% to over $5.0 million.
Regrettably this trend continues under the current board of
directors. With the hiring of Aurinia’s new CEO, base salary for
the CEO has gone from US$504,000 to US$650,000 (with a one-time
potential cash bonus of US$250,000 if Mr. Greenleaf survives under
Mr. Glickman’s watchful eye for more than a year), with equity
compensation increasing from 1,050,000 to 1,600,000 stock options.
Those represent single year increases of
nearly 30% on salary and over 50% on equity
compensation.
Finally, Aurinia’s Future is in
Shareholders’ Hands
In our years of dialogue with the Aurinia board and management
about the Corporation’s challenges, our message has remained
constant. We believe that Aurinia requires, and its shareholders
deserve, a board of directors that:
- Embodies corporate governance best
practices, rather than flouting them.
- Aligns board and executive compensation
and expenses with shareholders’ interests, rather than rewarding
non-performance.
- Demonstrates true independence from one
another and management (current and former), rather than looking
out for each other first.
- Supports and accelerates the
Corporation’s strategy execution, rather than sitting idly by as
the Corporation potentially squanders its tremendous
opportunity.
Upon their successful election, we expect that our nominees,
through the Governance & Nomination Committee and the
Compensation Committee, as applicable, will help implement
governance and compensation best practices at Aurinia to unlock
shareholder value and rebuild shareholder confidence, as laid out
in detail in ILJIN’s information circular in connection with the
upcoming Annual General Meeting of Shareholders to be held on
Wednesday, June 26, 2019, available at
www.AHealthierAurinia.com.
ILJIN’s Highly Qualified, Independent
Nominees
ILJIN has nominated three independent directors to strengthen
the board, remove conflicts and give Aurinia shareholders control
of their company:
- Dr. Robert Foster is largely
responsible for the discovery of voclosporin, the keynote drug upon
which Aurinia’s pipeline of pharmaceutical products is based, and
was the former CEO of both Isotechnika Pharma Inc., a predecessor
to Aurinia, and Aurinia itself. Dr. Foster is one of the most
respected pharmaceutical scientists in the world and brings a
proven ability in the discovery, development and commercialization
of pharmaceuticals.
- Mr. Soon-Yub (Samuel) Kwon has
extensive experience advising both domestic and international
healthcare-related companies over a broad range of transactional
and regulatory matters. He brings over 30 years of legal and
business acumen to his role as director.
- Dr. Myeong-Hee Yu has over 30
years of extensive international biotechnology experience, both as
a researcher and through numerous advisory and committee roles
within government and private industry. She has played a key role
in the development of Korea’s biotechnology industry, earning
numerous national and international awards and publishing over 120
articles in major scientific journals.
Aurinia has misleadingly stated that ILJIN is nominating three
directors, which when taken with ILJIN’s existing representative
Dr. Hyuek Joon Lee, will give ILJIN control of the board. Aurinia
conveniently neglects to acknowledge that ILJIN has expressly
recommended that shareholders WITHHOLD their votes for Dr. Lee and
that one of our three nominees is intended as a replacement. As
such, ILJIN does not want to, nor can it
with a three (3) director minority slate, take control.
Rather, ILJIN wants to give all shareholders more control. ILJIN’s
nominees have no prior relationships with each other of any nature
and have been selected because they have the requisite expertise
and can be expected to act independently of each other and of
ILJIN.
Aurinia has also made much noise of a contrived concern about
ILJIN’s nominees not having the expertise or qualifications that it
needs at this critical time and as it proceeds to
commercialization. As evident from the foregoing brief summary of
our nominees’ qualifications in relation to the discovery,
development and commercialization of pharmaceuticals, however,
there can be no doubt as to our nominees being very qualified for
the role. What should not be ignored is that 2 of the 3
incumbent directors that ILJIN has targeted for replacement (Dr.
Lee and Mr. MacKay-Dunn) have no commercialization expertise at all
and their replacement with our nominees would be an enhancement of
the board’s capabilities in that regard.
Don’t be fooled by Aurinia’s self-serving
mischaracterizations of our intentions, our nominees or their own
abilities to progress voclosporin through to
commercialization.
Manufacturing a Crisis: Aurinia’s
Unwillingness to Spare you this Proxy Battle
As shareholders should now appreciate, notwithstanding our
efforts to encourage Aurinia to improve its corporate governance
and compensation practices and reduce its expenses for the benefit
of all shareholders, ILJIN has been met by the Aurinia board with
deflection and denial at every turn. In fact, throughout our entire
period of dialogue on these issues at no time has Aurinia or any
member of its board of directors ever even acknowledged formally or
informally the validity of any of ILJIN’s concerns. Nonetheless,
Aurinia has clutched at the lowest of the low-hanging fruit of
corporate governance improvements in its management information
circular as it looks to appease the growing dissatisfaction of
shareholders at the upcoming Meeting. All of these steps toward
improvement were previously suggested by ILJIN and ignored.
Aurinia could have avoided this entire painful and costly
process if it had treated its shareholders with respect,
acknowledged its governance shortcomings and worked collaboratively
to resolve them, all entirely outside of public purview.
That outcome, of course, was never possible with the current
incumbent board, who default to equal measures of arrogance and
cronyism when called upon to lead.
The same is true as it relates to our proposed nominees and our
attempt to refresh and revitalize the board of directors and
dispatch the groupthink and conflicted allegiances that have served
only to impede the improvements that are so needed. Think about who
is being unreasonable:
First, ILJIN proposed simply
to substitute its existing nominee in the months prior to the
annual general meeting.
Aurinia said NO.
Second, ILJIN proposed three
(3) independent nominees to be mutually
agreed upon for election at the annual general meeting
and an additional one (1) which would ostensibly be ILJIN’s
nominee, but in the context of a proposal to search for an
additional director or director(s) for an expanded board of
directors, ensuring that ILJIN would never have real or apparent
control of the board of directors.
Aurinia said NO.
Aurinia instead proposed one (1) nominee for ILJIN, one (1)
nominee as Aurinia’s corporate legal counsel (as a stand-in for a
Canadian director to be chosen later and following the meeting) and
one (1) independent nominee to be mutually
agreed upon, again in the context of an expanded board
of directors with one (1) additional director yet to be
determined.
Consider that. This proxy contest has in essence resulted
from the failure of Aurinia to:
- accept Dr. Foster, the person
largely responsible for the discovery of voclosporin and with a
greater understanding of the drug and its potential than virtually
anyone, as a mutually agreeable candidate in lieu of Aurinia’s own
corporate counsel (as a stand in for a Canadian “player to be named
later”…a dubious governance practice in its own right that kicks
sand in the face of shareholder rights); and
- negotiate on two (2) additional
independent nominees on a mutually agreed
basis rather than simply providing ILJIN a right to
provide input on the director selection process. While ILJIN has
now proposed Dr. Yu and Mr. Kwon as highly qualified and
independent directors to fill those roles, had Aurinia been at all
willing to discuss other candidates it is certain that mutually
agreeable candidates could have been found.
Far from an effort by ILJIN to take real or effective control of
the board of directors of Aurinia, this proxy contest simply
further highlights the abject failure of the current board of
directors of Aurinia to elevate the best interests of Aurinia above
their personal ambitions and maintaining their cadre of close
personal relationships on the board.
Rather than attacking our nominees, attempting to subvert
shareholder democracy at every turn and engaging in a public
campaign predicated upon deception and trickery, Aurinia could have
worked in your best interests to collaboratively agree with ILJIN
qualified independent directors. Instead, the lasting legacy of
self-preservation and entrenchment at the expense of pragmatism and
practicality has prejudiced shareholder best interests yet
again.
You have the opportunity to help rectify the failures of this
board to negotiate a reasonable resolution by electing the
Concerned Shareholder’s independent nominees to the board of
directors. Don’t let this opportunity pass.
For more information or if you require assistance with voting
your accompanying GREEN universal proxy or voting instruction form,
please contact our proxy solicitation agent, Gryphon Advisors Inc.,
using the contact information set out below and on the front and
back pages of the Proxy Circular.
We believe the Proposed Nominees have the required discipline
and skill set to take Aurinia to the next phase of its existence
and are confident that you will come to the same conclusion. We
welcome all Shareholders to join us and vote for change. We look
forward to your support.
Aurinia’s future is in your hands.
Sincerely,
/s/
(signed) “Young-Hwa Kim”Chief Executive OfficerILJIN SNT Co.,
Ltd.
Advisors and Counsel
Stikeman Elliott LLP is acting as Canadian legal counsel to
ILJIN. Gryphon Advisors Inc. has been engaged as proxy solicitation
agent and Gagnier Communications has been engaged by ILJIN as
communications advisor.
Legal Notices and Disclaimers
The data, information and opinions contained or referenced
herein (collectively, the “Information”) is for general
informational purposes only for the shareholders in order to
provide the views of ILJIN regarding certain changes that it is
requesting to the composition of the Aurinia board of directors and
other matters which it believes to be of concern to shareholders
described herein. The Information is not tailored to specific
investment objectives, the financial situation, suitability or
particular need of any specific person(s) who may receive the
Information and should not be taken as advice in considering the
merits of any investment decision. The views expressed in the
Information represent the views and opinions of ILJIN, whose
opinions may change at any time and which are based on analysis of
disclosure and filings with respect to and/or made by Aurinia and
other issuers that we consider to be comparable to Aurinia, and
from other third party reports (see “Disclaimer Respecting Publicly
Sourced Information” in the Circular, a copy of which is available
on SEDAR at www.sedar.com or on www.aHealthierAurinia.com). ILJIN
disclaims any obligation to publicly update the Information, except
as required by applicable law.
The Information contains forward-looking statements or
forward-looking information within the meaning of applicable
securities laws (collectively, "forward-looking
statements"), including in respect of ILJIN and the impact of
ILJIN’s Nominees on the Corporation. All statements and
Information, other than statements of historical fact, contained or
referenced herein are forward-looking statements and
forward-looking information, including, without limitation,
statements regarding activities, events or developments that ILJIN
expects or anticipates may occur in the future. Such
forward-looking statements and information can be identified by the
use of forward-looking words such as “will”, “expect”, “intend”,
“plan”, “estimate”, “anticipate”, “believe” or “continue” or
similar words and expressions or the negative thereof. There can be
no assurance that the plans, intentions or expectations upon which
such forward-looking statements and information are based will
occur or, even if they do occur, will result in the performance,
events or results expected.
ILJIN cautions readers not to place undue reliance on
forward-looking statements and information contained or referenced
herein, which are not a guarantee of performance, events or results
and are subject to a number of risks, uncertainties and other
factors that could cause actual performance, events or results to
differ materially from those expressed or implied by such
forward-looking statements or information, including but not
limited to those set forth in the Circular under the heading
“Forward-Looking Statements and Information” and those risks and
uncertainties detailed in the continuous disclosure and other
filings of Aurinia and certain members of Aurinia’s peer groups
with applicable securities regulatory authorities, copies of which
are available on SEDAR at www.sedar.com or on the Electronic Data
Gathering, Analysis, and Retrieval at www.sec.gov. Shareholders are
urged to carefully consider those factors.
The forward-looking statements and information contained or
referenced herein are expressly qualified in their entirety by this
cautionary statement. The forward-looking statements and
information contained or referenced herein are made as of the date
of the ILJIN Circular and ILJIN undertakes no obligation to
publicly update such forward-looking statements or information to
reflect new information, subsequent events or otherwise, except as
required by applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190610005681/en/
Investors:Gryphon Advisors Inc.North American Toll-Free Number:
1-833-261-9730Outside North America, Banks, Brokers and Collect
Calls: 1-416-661-6592Email: inquiries@gryphonadvisors.ca
Media:Gagnier CommunicationsDan Gagnier / Jeffrey
Mathews1-646-569-5897
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024